Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 9/20 | 0.53 |
| ▸ | FEN1 | P39748 | 8/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | APOL1 | O14791 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14855805 | 1.00 | ALOX5AP (0.53) | ALOX5APFEN1TBXA2RDPP4DPP7 | |
| SCHEMBL14856078 | 0.90 | ALOX5AP (0.53) | ALOX5APFEN1APOL1 | |
| SCHEMBL15153322 | 0.90 | ALOX5AP (0.53) | ALOX5APFEN1APOL1 | |
| SCHEMBL14856175 | 0.84 | ALOX5AP (0.58) | ALOX5APFEN1HTR6 | |
| SCHEMBL14856174 | 0.84 | ALOX5AP (0.58) | ALOX5APFEN1HTR6 | |
| SCHEMBL14855603 | 0.81 | RB1 (0.49) | ALOX5APFEN1TBXA2R | |
| SCHEMBL14855604 | 0.81 | RB1 (0.49) | ALOX5APFEN1TBXA2R | |
| SCHEMBL15153496 | 0.80 | PSEN1 (0.49) | ALOX5APFEN1HTR6HDAC8 | |
| SCHEMBL14855834 | 0.80 | PSEN1 (0.49) | ALOX5APFEN1HTR6HDAC8 | |
| SCHEMBL15924423 | 0.79 | ALOX5AP (0.68) | ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203734-A1 | ANTI-INFLAMMATORY AGENTS | GRAINGER DAVID JOHN (GB) | 2013-08-08 | — | — | US | claimed |
| EP-2580197-A1 | ANTI-INFLAMMATORY AGENTS | Cambridge Enterprise Ltd. (GB) | 2013-04-17 | — | — | EP | claimed |
| WO-2011154695-A1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-12-15 | — | — | WO | claimed |
| US-20130203734-A1 | ANTI-INFLAMMATORY AGENTS | GRAINGER DAVID JOHN (GB) | 2013-08-08 | — | — | US | disclosed |
| US-20130203734-A1 | ANTI-INFLAMMATORY AGENTS | GRAINGER DAVID JOHN (GB) | 2013-08-08 | — | — | US | disclosed |
| EP-2580197-A1 | ANTI-INFLAMMATORY AGENTS | Cambridge Enterprise Ltd. (GB) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011154695-A1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011154695-A1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203734-A1 | ANTI-INFLAMMATORY AGENTS | IL6, TNF, IL1B | ALOX5AP 332/4885FEN1 3636/4885TBXA2R 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.